Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06614127

Continuous Glucose Monitoring: A Pilot Study

The purpose of this study is to evaluate connectivity of the FDA approved DexCom G7® continuous glucose monitor in the operating room. Continuous glucose monitors are applied to the skin and a thin sampling filament is inserted into the skin and measures blood sugar in the interstitial fluid. The DexCom G7® is used regularly outside of the operating room to monitor blood sugar, however the use of the device in the operating room environment has been limited by connectivity issues. This study will assess device connectivity at different monitoring sites.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Loma Linda University Troesch Medical Center

Loma Linda, California, 92354, United States

About this study

This feasibility pilot study will assess connectivity of the DexCom G7® continuous glucose monitoring device (CGM) in the operating room environment at different locations on the body. The investigators believe device connectivity is affected by use of electrocautery. The monitoring sites were selected to limit electromagnetic interference from electrocautery.

One cohort will have the CGM device placed on the deltoid and the electrodispersive pad placed on the thigh and the other cohort will have the CGM device placed on the thigh with the electrodispersive pad on the opposite thigh.

Study personnel will note when electrocautery is used throughout the surgery and observe if the DexCom G7® continues to maintain connectivity with the receiver and provides a glucose reading. Comparing the timing of electrocautery use with connectivity to the DexCom G7® receiver provides important insight to the relationship between electrocautery and device connectivity.

The CGM readings will solely be used for feasibility purposes for this study and not for determining interventions for the subjects.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults age 18 and above able to consent for themselves
  • Willingness and ability to participate in study procedures
  • Surgery length estimated 3 hours or longer

Exclusion criteria

  • Cardiothoracic surgical patients
  • Plan for intraoperative radiologic imaging
  • Patients on IV infusion of insulin prior to surgery
  • Anemia with hemoglobin less than 7
  • Patients on hydroxyurea
  • Patients with known adhesive allergies
  • Pregnant women

Treatment and study plan

Dexcom G7® sensor placed in upper arm and positioned over deltoid

Device

For the "subjects with Dexcom G7® sensor placed in the upper arm and positioned over the deltoid" cohort, study personnel will place the Dexcom G7® sensor on the subjects' deltoid and the electrodispursive pad on the thigh.

Dexcom G7® sensor placed in anterior thigh

Device

For the "subjects with Dexcom G7® sensor place in anterior thigh" cohort, study personnel will place the Dexcom G7® sensor in the anterior thighs and the electrodispursive pad will be placed on the opposite thigh.

Primary outcomes

  1. Effect of DexCom G7® sensor position on receiver connectivity during and after electrocautery use.

    Time frame: Change between baseline at start of procedure and completion of procedure, up to 6 hours.

    Connectivity will be recorded continuously from start to finish of the procedure.

    The percentage of time the Dexcom G7® device remains connected during the subject's surgical case will be measured. The effect of electrocautery on CGM connectivity will be assessed by comparing the start and stop times in connectivity to the start and stop times of electrocautery. Connectivity time greater than 80% is considered highly effective. Connectivity time between 20% and 80% is considered effective. Connectivity time less than 20% is considered sub-optimal.

Sponsors and collaborators

Lead sponsor

Loma Linda University

Other

Registry information

Official study title

Continuous Intraoperative Glucose Monitoring: A Pilot Study

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Sep 26, 2024
Registry last updated
Aug 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.